Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
AssigneeIrm LLC
InventorsJohn Welsh, Garret Hampton
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing, monitoring the progression of, and treating a prostate disorder based upon genes that are differentially expressed in prostate disorders. Also disclosed are methods for identifying agents useful in the treatment of a prostate disorder, methods for monitoring the efficacy of a treatment for a prostate disorder, methods for inhibiting the proliferation of a prostate cell, and prostate-specific vectors including the promoter of these genes.
Claims22
A method for screening a subject for a prostate disorder or at risk of developing a prostate disorder, the method comprising:
- a) detecting a level of expression of at least one gene selected from the group consisting of LIM (SEQ ID NO:
- 5), pyrroline 5-carboxylate reductase (SEQ ID NO:
- 6) and SIM2 (SEQ ID NO:
- 7) in a sample of prostate tissue obtained from the subject to provide a first value, and
- b) comparing the first value with a level of expression of the at least one gene in a sample of prostate tissue obtained from a disease-free subject, wherein a greater expression level in the subject sample compared to the sample from the disease-free subject is indicative of the subject having a prostate disorder or at risk of developing a prostate disorder.
A method for monitoring the progression of a prostate disorder in a subject having, or at risk of having, a prostate disorder comprising measuring a level of expression of at least one gene selected from the group consisting of LIM (SEQ ID NO:
- 5), pyrroline 5-carboxylate reductase (SEQ ID NO:
- 6) and SIM2 (SEQ ID NO:
- 7) over time in a prostate tissue sample obtained from the subject, wherein an increase in the level of expression of the at least one gene over time is indicative of the progression of the prostate disorder in the subject.
A kit for use in determining expression level of a gene selected from the group consisting of LIM (SEQ ID NO:
- 5), pyrroline 5-carboxylate reductase (SEQ ID NO:
- 6) and SIM2 (SEQ ID NO:
- 7) in a subject having or being at risk of developing a prostate disorder, the kit comprising a probe that is capable of detecting expression of the gene.
Dependencies are inferred from the claim text.